Ann: BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS, page-464

What chance does Biotron have of curing COVID-19?

Good to very good, based on the evidence to date. Thus evidence begins with their initial work with SARS1, advanced with their HIV research using the same technology, and has proven extremely successful in their latest C19 trials.

I first became interested in their C19 work when becoming aware of their latest coronavirus patent on 26th December 2019; an auspicious date. This patent was renewing their SARS1 work where the ion channeling of several strains of human corona viruses was blocked. Could they repeat it for SARS2?

The protein responsible for this IC in SARS1 is as good as identical in SARS2, and has a corresponding protein in HIV, where Biotron have now managed to clear reservoirs of hidden HIV using the same technology. Phase 3 trials in HIV will commence in 2022, which is the difference in a failed or successful drug, though still no guarantee of final success.

These latest C19 results are outstanding. specifically, the fact that the mice engineered to be more prone to infection by having increased ACE2 receptor cells, but continued to grow healthily with no increased levels of cytokines, is a perfect result.

These results have been an entry ticket to CTAP, something that few drugs have achieved yet, and leaves most of the competition behind, not that the issue of competition is much of an issue in a pandemic.

The fast track trial process will be much faster than Merck and Pfizer's process as BIT225 already has the necessary safety profile to advance to phase 2/3, which Pfizer is just beginning now. it's nice to know that we are in fact in avjust as good, uf not better, than these mammoths. Well, a forthcoming CTAP acceptance will demonstrate that.

Will the recent excellent mice trials translate into the same in humans? Sure they will, thanks to nine HIV trials that have proven successful. For those unaware, SARS2 is less nasty than HIV, and treating the cytokine storm compared to immunodeficiency is far simpler. But BIT225 has shown great resilts in treating both, albeit in mice only with C19.

Before all this, a new trial other than CTAP will begin shortly, so that from an investment perspective, we can invest proportional ly on these forthcoming 'mini' trial and be prpared to go 'all in' for CTAP if the advanced trial is successful.

Personally, Im already all in as of last Friday. Not to be recommended though.